Novartis to Pay $245 Million in ’Pay for Delay’ Settlement
Novartis has agreed to pay a total of $245 million to settle lawsuits filed by direct purchasers, indirect purchasers and retailers accusing it of colluding with Par Pharmaceutical to delay the launch of a generic version of its Exforge (valsartan/amlodipine) hypertension drug.
